Summary
An American study investigated whether selenium administration may suppress a specific type of the human immunodeficiency virus. 262 participants infected with HIV initiated the treatment. 141 participants were treated with a selenium product (200 µg), and 121 participants received a placebo product during the first 9 months of this study. In total, 174 participants completed the first 9 months of this study. Several parameters were measured at the beginning of the study, and a more detailed assessment was executed after 9 months and 18 months. A significant increase in selenium levels was shown in the selenium group. Moreover, this group showed a lower level of human immunodeficiency parameters in the blood than the placebo group, which indicates that selenium could be an effective, simple, and cheap additional therapy for HIV patients. Further information can be found in the study.
References
Hurwitz et al.